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Abstract
Background: A number of non-malignant diseases that share similar morphological features as
gastrointestinal stromal tumor (GIST) have been reported. Co-existence of GIST with these other
diseases is rarely recognized or reported.
Case presentation: We report a case of a 62 year-old man with long-term stable control of
metastatic GIST with systemic therapy, presented with an apparent intra-abdominal progression
but not supported by imaging with positron emission tomography. Subsequent resection of the
intra-abdominal tumor identified a non-malignant fibroid.
Conclusion: Differentiating localized progression of GIST from other diseases has important
prognostic and therapeutic implications. The potential for co-existence of non-malignant soft tissue
neoplasm should always be considered.
Background
The finding of gain-of-function mutation of KIT has revo-
lutionized the treatment of advanced gastrointestinal stro-
mal tumor (GIST). This has subsequently led to
development of effective systemic therapy utilizing tyro-
sine kinase inhibitors (TKI). Imatinib is the prototype TKI
that was initially reported to achieve a partial response
rate of 53.7% and stable disease rate of 27.9%[1]. With
the increasing use of TKI in the treatment of advanced
GIST, the pattern of disease evolutions are changing
which will ultimately impact on the approach to manage-
ment.
A number of soft tissue neoplasm share many similarities
in the morphological and immunophenotypic profiles
with GIST. Aggressive fibromatosis (AF) and keloid type
fibromatosis scar tissues are distinct soft tissue tumors. AF
is a fibroproliferative disease with a propensity for intra-
abdominal presentation[2]; it may be locally aggressive
but generally lacks metastatic potential. Keloid and hyper-
tropic scars are closely related entities that are non-malig-
nant and characterized histologically by increased
connective tissue deposition, increased blood vessel den-
sity and increased cellular deposition[3,4].
In this report, we present a case of a man who had been
treated with imatinib and achieved long-term stable
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advanced GIST, but presented with localized proliferation
of soft-tissue neoplasm mimicking GIST.
Case presentation
A previously healthy, 62 year old man was diagnosed with
a gastric antral tumor after investigations for symptomatic
anemia. A barium swallow confirmed the presence of
tumor causing subacute gastric outlet obstruction. Lapar-
oscopy identified a gastroduodenal tumor and synchro-
nous bilobar liver metastases. No peritoneal disease was
identified. The primary tumor was completed excised and
a liver biopsy was performed intra-operatively. Histopa-
thology was consistent with metastatic malignant gas-
trointestinal stromal tumor, with typical spindle cell
features on light microscopy. C-KIT was positive and the
mitotic rate was 60/50 per high power fields (Figure 1).
Subsequent analysis of the tumor revealed an in-frame
deletion of Exon 11 in the C-KIT gene.
Post-operatively, this man recovered well from his surgery
and was commenced on imatinib 600 mg daily; he subse-
quently required dose-reduction to 400 mg daily due to
grade 3 neutropenia. He still had residual hepatic meta-
static disease which was visible on computerized tomog-
raphy [CT] scan, and was FDG-avid on positron emission
tomography [PET] evaluation. For a period of eighteen
months after surgery, imatinib was tolerated well and
achieved good disease control. CT and PET imaging dur-
ing this period revealed regression of size of the liver
metastases. After two years of therapy, however, a CT scan
revealed an increase in size of a dominant segment VI
hepatic metastasis which was treated with radiofrequency
ablation. He was then maintained on imatinib at 600 mg
daily with subsequent disease control.
At four and half years from diagnosis, an asymptomatic
infrapyloric mesenteric mass was identified on a surveil-
lance CT which progressively increase in size over the next
two months (Figure 2). A PET scan paradoxically revealed
no glucose avidity of this mesenteric tumor (Figure 3).
At subsequent laparotomy, the tumor was found to be
lying within the peritoneal leaves of the mesocolon
extending from the origin of the superior mesenteric ves-
sels to the inferior pancreatico-duodenal vessels. Histopa-
thology showed a tumour mass composed of spindle
shaped fibrocytic/fibroblastic like cells amongst interven-
ing collagen (Figure 4) with low mitotic rate (less than 1
per 50 hpf). Immunoperoxidase staining was positive for
C-KIT but negative for CD34 and S100. Genetic analyses
did not identify the previous C-KIT Exon 11 in-frame dele-
A representative immunohistochemical section of the  resected primary tumor – diffuse c-KIT staining Figure 1
A representative immunohistochemical section of 
the resected primary tumor – diffuse c-KIT staining.
A section of computerized tomography [CT] scan Figure 2
A section of computerized tomography [CT] scan. 
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tion or mutations of other Exons 11, 9, 13 and 17 and
PDGFRA Exon 18.
Imatinib was continued 600 mg daily, with brief cessation
during the peri-operative period, as metastatic GIST
remained radiologically stable. No specific adjuvant ther-
apy for the soft-tissue tumor was employed post-opera-
tively.
Discussion
In this patient with metastatic GIST, the development of
the mesenteric tumor four years after the institution of
imatinib initially suggested disease relapse. Debulking
surgery remains a recognized standard practice in the case
of local progression where such procedure is associated
with prolonged survival with the elimination of imatinib
resistance clones[5]. However, in rare instances as illus-
trated in this case, consideration for co-existence of
another disease will need to be considered.
This patient underwent surgery with the pre-surgical diag-
nosis of a localized progression; surgery was aimed to
achieve disease control with the elimination of a presum-
ably localized imatinib resistance tumor. Post-surgery, the
histopathologic findings revealed a tumor with reduced
cellularity and low mitotic activity consistent with the pre-
operative non-glucose avid PET findings. Collaborative
pathologic review was obtained and excluded diagnosis of
a recurrent GIST. However, a definitive uniform diagnosis
could not be made. The possible differential diagnoses of
this soft-tissue tumor include aggressive fibromatosis (AF)
or intra-abdominal keloid type fibrocollagenous scar.
Immunohistochemistry was positive for C-KIT, which is
unusual in AF or intra-abdominal keloid type fibrocolla-
genous scar. Mutation analysis that was performed on the
mesenteric tumor further clarify that this mass, which was
absent of Exon 11 C-KIT mutation, was different from the
Exon 11 C-KIT mutation positive of the original resected
antral GIST.
Histologically, AF lies on a spectrum of disorders charac-
terized by excess proliferation of fibroblast-like spindle
cells[6]. These cells are monoclonal neoplasms[7] with
low cellularity and rare mitoses. Most are associated with
germline or somatic mutations of WNT pathway (APC or
CTNNB1). Some studies [8-11] have demonstrated clini-
cal and radiological benefits of imatinib in treatment of
AF.
There is very limited literature on intra-abdominal keloid
type fibrocollagenous scar. The scar in this patient was
presumably formed from previous surgical laparotomy.
There is growing evidence to suggest that Transforming
Growth Factor β[12] is implicated in keloids and other
benign fibroproliferative diseases as well as formation of
adhesions after abdominal operations[13]. Although such
clinical entities are well-described in literature when they
are manifested cutaneously, there is no information on
intra-abdominal manifestation.
The immunophenotypic profiles of GIST, AF and keloid
may overlap. Fibromatoses may stain for vimentin,
smooth muscle actin, and desmin. In some series,
fibromatosis did not stain for CD34 or S-100 protein,
while CD34 staining and occasional S-100 protein posi-
tivity were seen in GIST[2,14]. It has been suggested that
Whole body positron emission tomography [PET] Figure 3
Whole body positron emission tomography [PET]. 
No abnormal foci of increased metabolism of FDG can be 
identified.
Hematoxylin & eosin stained section of infrapyrolic  mesenteric mass Figure 4
Hematoxylin & eosin stained section of infrapyrolic 
mesenteric mass. Spindle shaped fibrocytic/fibroblastic like 
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differences in CD34 immunostainin might be helpful in
distinguishing between them[14]. C-KIT staining in AF is
controversial. Up to 75% of cases in one series were C-KIT
positive[2] but other reports have concluded that most
AF's do not express demonstrable levels of this imatinib
target. In cutaneous fibrocollagenous scar, smooth muscle
actin is stained more commonly in hypertropic scar and to
the lesser extent on keloid scars[12,15]. More impor-
tantly, there is no report of C-KIT staining in fibrocolla-
genous scars.
Conclusion
The long stable disease control, the absence of glucose
avidity of pre-operative PET and the absence of the C-KIT
mutation in the mesenteric tumor were all features that
might have suggested the possibility of an alternative
diagnosis to GIST recurrence. Although surgical resection
of this mesenteric mass may remain necessary, a correct
diagnosis has important implication for his future sys-
temic therapy. This case report highlights the importance
of recognizing the coexistence of other diseases in patients
with chronic GIST.
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